Listing 8.07 Genetic Photosensitivity Disorders in 2026: The One Skin Listing That Skips Functional Testing, the 8.07B Extensive-Lesion and Protective-Environment Paths, and How Rare Genodermatoses Actually Win at Step 3

Section 8.00 of the Blue Book has one strange corner that behaves differently from every other skin rule. Listing 8.07 does not ask you to prove functional loss under the same four paragraph structure that 8.08 burns and 8.09 chronic skin conditions require. Instead, 8.07 splits into two paths. 8.07A covers xeroderma pigmentosum. If you have XP with the right genetic testing, you meet Step 3 on the diagnosis alone. No hand function testing. No gait testing. No perineal contracture measurement. 8.07B covers other genetic photosensitivity disorders and requires either extensive skin lesions lasting 12 months or an inability to function outside a highly protective environment for 12 months. This piece walks through both paths as they read in Appendix 1 to Subpart P of Part 404 in 2026, why the SSA carved out this exception for XP, and how rare disorders like erythropoietic protoporphyria, Cockayne syndrome, Bloom syndrome, hydroa vacciniforme, and trichothiodystrophy actually get approved.

Why 8.07 Is the Only Skin Listing Without Functional Testing

Every other skin listing in Section 8.00 requires proof of functional loss. Listing 8.09 for chronic skin conditions asks for four paragraph outcomes covering fine and gross hand movements, single-arm plus assistive device, standing from a seat, and standing or walking with both legs. Listing 8.08 for burns uses the same four paragraphs. Listing 8.04 for hidradenitis suppurativa uses the same paragraphs. Even mycosis fungoides under 8.05 requires either extensive skin involvement or specific systemic treatment. All of them push the analyst into functional testing at Step 3.

8.07 breaks that pattern for XP because the disease itself is uniformly severe. XP patients cannot tolerate normal ultraviolet exposure. Their DNA nucleotide excision repair is defective. Every episode of sun exposure produces cumulative damage. The Skin Cancer Foundation reports that XP patients under 20 years old have a 10,000-fold increased risk of nonmelanoma skin cancer and a 2,000-fold increased risk of melanoma compared to the general population. Median age at first skin cancer in XP is 8 years. Median life expectancy with pure cutaneous XP is around 32 years, and much shorter for XP with neurological involvement.

SSA decided in the 2016 skin listings revision that no case-by-case functional testing was needed for XP. The clinical picture is severe enough that Step 3 approval on diagnosis alone is appropriate. The 2026 Blue Book preserves that carveout.

The Exact Text of Listing 8.07 in 2026

Listing 8.07 reads:

8.07 Genetic photosensitivity disorders. Established as described in 8.00E.

A. Xeroderma pigmentosum. Consider under a disability from birth.

B. Other genetic photosensitivity disorders, with:

1. Extensive skin lesions that have lasted or can be expected to last for a continuous period of at least 12 months, or
2. Inability to function outside of a highly protective environment for a continuous period of at least 12 months (see 8.00E4).

Two features of that language matter more than they look. First, XP under 8.07A says consider under a disability from birth. That phrase means the onset date for XP claimants defaults to birth, not to filing date. This affects retroactive benefits for adult XP claimants who lived without ever filing before, and it affects childhood SSI claims when parents file for their child.

Second, 8.07B does not use the word marked or the word severe. It uses extensive and continuous period of at least 12 months. That is a duration test and a body coverage test, not a functional test. The functional path only comes in under 8.07B2 through the highly protective environment concept, which is defined at 8.00E4 and covered later in this article.

How 8.00E Establishes a Genetic Photosensitivity Disorder

Section 8.00E of the Blue Book explains what evidence establishes a genetic photosensitivity disorder for purposes of Listing 8.07. The relevant paragraphs read:

• 8.00E1 Genetic photosensitivity disorders are inherited conditions in which the skin responds abnormally to ultraviolet light. Diagnosis is established by clinical findings, laboratory findings including genetic testing when available, and family history.
• 8.00E2 Signs and laboratory findings that support a diagnosis include reports of clinical features, family history, and, when available, genetic testing showing pathogenic variants known to cause the disorder.
• 8.00E3 For XP, SSA requires clinical findings and either genetic testing showing pathogenic variants in one of the XP complementation groups (XPA through XPG or XPV) or laboratory findings showing defective DNA repair such as unscheduled DNA synthesis testing or complementation studies.
• 8.00E4 Highly protective environment for purposes of 8.07B2 means an environment that eliminates or blocks the source of UV radiation to the extent required to prevent the patient's skin lesions or systemic manifestations from worsening. This can include full window film blocking UVA and UVB, protective clothing covering all exposed skin, face shields, and avoiding fluorescent lighting when documented as a trigger.

The genetic testing piece is the crucial 2026 update. When SSA revised Section 8 in 2016, DNA testing for XP was still expensive and not universally available. Today, gene panels for XPA, XPB (ERCC3), XPC, XPD (ERCC2), XPE (DDB2), XPF (ERCC4), XPG (ERCC5), and XPV (POLH) are available through commercial labs at costs of a few hundred dollars. POMS DI 23022.920 was updated in April 2026 to include genetic testing including UV-induced chromosomal changes with abnormal DNA repair, complementation studies, and gene sequencing as the preferred documentation for XP claims. Skin biopsy is also suggested medical evidence.

The XP Complementation Groups

XP is not a single disease. It is a family of at least eight distinct genetic conditions that share the same clinical phenotype. Each complementation group corresponds to a defect in a specific step of nucleotide excision repair. The groups differ in severity and in whether neurological involvement is present.

• XPA (XPA gene, chromosome 9): often severe cutaneous disease with early neurological involvement including sensorineural hearing loss, ataxia, cognitive decline, and peripheral neuropathy.
• XPB (ERCC3): rare, often overlaps with trichothiodystrophy or Cockayne syndrome features.
• XPC (XPC): most common form in the United States. Predominantly cutaneous with less neurological involvement. Still severe skin cancer risk.
• XPD (ERCC2): variable severity. Overlap syndromes with Cockayne and trichothiodystrophy are common.
• XPE (DDB2): mildest cutaneous form. Later onset skin cancers.
• XPF (ERCC4): variable severity. Some late-onset neurological forms.
• XPG (ERCC5): can overlap with Cockayne syndrome features. Severe forms exist.
• XPV (POLH): variant form. Later onset skin cancers than classic XP. Fewer freckles at young age. Diagnosed after adult-onset multiple skin cancers.

Any of these groups meet Listing 8.07A once diagnosis is established by clinical and laboratory findings. The rule text does not distinguish among groups.

Other Genetic Photosensitivity Disorders Under 8.07B

8.07B is the fallback path for genetic photosensitivity disorders other than XP. The rule captures a family of rare conditions that share UV sensitivity but do not fit the XP genotype.

Erythropoietic Protoporphyria (EPP)

EPP results from a deficiency of ferrochelatase, the enzyme that catalyzes the final step in heme biosynthesis. Protoporphyrin IX accumulates in red blood cells, plasma, and skin. Sun exposure activates protoporphyrin IX and generates reactive oxygen species that damage skin and blood vessels. Patients feel burning and stinging pain within minutes of sunlight exposure, often before any visible skin change. Later they develop edema, erythema, and thickened skin over sun-exposed areas. Sudden onset of severe photosensitivity in childhood is the classic presentation.

EPP patients rarely have severe visible skin lesions between attacks. The disability picture is dominated by the inability to be outside during daylight hours. This makes 8.07B2 the natural path. The claimant needs to document that they cannot function outside a highly protective environment for 12 months. Afamelanotide implants approved by the FDA in 2019 allow modest sun exposure for some EPP patients, but many still cannot tolerate daily outdoor activity. Documentation includes plasma or erythrocyte protoporphyrin levels, FECH gene testing, and detailed exposure history.

Cockayne Syndrome

Cockayne syndrome combines UV sensitivity with growth failure, microcephaly, neurological regression, cachexia, and premature aging. Types I, II, and III exist based on age of onset and severity. Type II is congenital and severe. Type I onset is in early childhood. Type III is later onset and milder. Cockayne is caused by mutations in ERCC6 (CSB) or ERCC8 (CSA). Cases with severe neurological features may also meet listings in Section 11.00 or 12.00. Cases with predominant cutaneous photosensitivity fit 8.07B either through extensive skin lesions or through the protective environment test.

Bloom Syndrome

Bloom syndrome results from mutations in the BLM gene encoding a RecQ helicase. Patients have short stature, telangiectatic sun-induced facial rash, high cancer predisposition, immune deficiency, and diabetes. Classic Bloom syndrome facial telangiectasia is triggered by sun and typically starts in infancy. Extensive facial and forearm skin lesions after limited sun exposure often qualify under 8.07B1. Concurrent hematologic cancers may add a Section 13 listing.

Hydroa Vacciniforme

Hydroa vacciniforme is a rare photosensitivity disorder of childhood characterized by vesicular eruption on sun-exposed skin, often followed by scarring. Chronic hydroa vacciniforme lymphoproliferative disorder is a Epstein-Barr virus associated form seen in Asia and Latin America with malignant potential. Documentation includes phototesting, skin biopsy showing epidermal necrosis and intraepidermal vesicles, and EBV testing when the lymphoproliferative variant is suspected.

Trichothiodystrophy

Trichothiodystrophy is often photosensitive form (PTTD) caused by mutations in ERCC2, ERCC3, GTF2H5, or MPLKIP. Combines brittle sulfur-deficient hair with intellectual disability, short stature, and ichthyosis. Photosensitive TTD may fit 8.07B when documentation supports 12-month duration.

Other Rare Photosensitivity Disorders

Rothmund-Thomson syndrome (RECQL4), Kindler syndrome (FERMT1), and photosensitive forms of hereditary porphyrias other than EPP can also fit 8.07B when the criteria are met. Genetic confirmation is helpful but the rule does not require it in every case.

Extensive Skin Lesions Under 8.07B1

Extensive is not defined in 8.07 itself. Section 8.00B2 defines extensive skin lesions as lesions that involve multiple body sites or a critical body area, and that result in a very serious limitation, or that involve a smaller area in a critical location. Critical body areas include the palms of the hands, soles of the feet, perineum, inguinal area, or the axilla, where the skin lesions produce a serious limitation in function.

For a genetic photosensitivity disorder claim under 8.07B1, extensive skin lesions typically means chronic facial and dorsal hand involvement, chronic ear and lip involvement, or multi-site chronic lesions that persist through routine treatment and photo protection. Cumulative sun damage in XP variants (POLH) that manifests as multiple skin cancers by age 30 across the face and forearms fits extensive skin lesions well. Chronic hydroa vacciniforme scarring across cheeks, forehead, dorsal hands, and forearms fits extensive skin lesions well.

Highly Protective Environment Under 8.07B2 and 8.00E4

The protective environment path is the most powerful part of 8.07B for patients whose skin lesions are less visible but whose lives are severely restricted by the disorder. Section 8.00E4 defines highly protective environment as an environment that eliminates or blocks the source of UV radiation to the extent required to prevent the patient's skin lesions or systemic manifestations from worsening.

This can include:

• Full window film blocking UVA and UVB in the home and vehicles.
• Protective clothing covering all exposed skin whenever any UV exposure is possible.
• Face shields.
• Avoidance of unshielded fluorescent lighting when documented as a trigger.
• Restriction of outdoor activity to nighttime or only to fully shaded environments.
• UV-blocking eyewear for XP patients with ocular involvement.

The claimant does not have to prove that all of these measures are in place. The rule asks whether the claimant is unable to function outside such an environment for 12 continuous months. A functional statement from the treating dermatologist describing the required environment, plus a home assessment note or a photograph of installed UV filters, plus a personal statement or diary describing daily restrictions, can build a strong record.

Documentation Package That Wins 8.07 Cases

For 8.07A xeroderma pigmentosum

• Genetic testing report identifying a pathogenic variant in one of the XP complementation groups (XPA through XPG or XPV/POLH).
• Or laboratory findings showing defective DNA repair such as unscheduled DNA synthesis testing or complementation studies.
• Skin biopsy showing UV damage.
• Dermatology records documenting clinical features consistent with XP including freckling in sun-exposed areas by age 2, atrophy, telangiectasias, and skin cancer history.
• Ophthalmology records if ocular involvement is present.
• Neurology records if neurological involvement is present.

For 8.07B other genetic photosensitivity disorders

• Genetic testing report showing pathogenic variant, when available.
• Biochemical testing appropriate to the disorder (protoporphyrin levels for EPP, growth curves for Cockayne, chromosome breakage studies for Bloom).
• Photograph documentation of skin lesions across multiple dates.
• Treating physician statement describing required protective environment for 8.07B2 claims.
• Personal function statement describing daily restrictions.
• Third-party function reports from family members.

Worked Case Examples

Case One, Miguel, 12, Texas

Miguel was diagnosed with XPC by gene panel at age 7 after presenting with severe freckling on the cheeks and multiple basal cell carcinomas of the face by age 5. His mother filed a childhood SSI claim in 2024 after the family had to modify their home with full UV filtration and Miguel could no longer attend regular school. Genetic testing confirms biallelic pathogenic variants in XPC. Dermatology records document 14 non-melanoma skin cancers by age 11 requiring surgical excision. He wears full protective clothing and a face shield during all daytime outdoor activity. 8.07A is met. Onset date defaults to birth per the rule text. SSI approved with medical improvement not expected review interval.

Case Two, Aisha, 28, Michigan

Aisha has EPP diagnosed at age 4 by erythrocyte protoporphyrin levels of 3,400 (normal under 80) and FECH gene testing showing compound heterozygous pathogenic variants. She cannot tolerate direct sunlight for more than three minutes without severe burning pain. She works from home, drives only at night, and requires full UV window film in her car and home. She has tried afamelanotide implants with modest benefit but still cannot function during daylight hours outdoors. She filed for SSDI at age 27 after leaving her office job because commuting became impossible. Treating hematology provided a statement that Aisha requires a highly protective environment continuously and has done so for the past 5 years. 8.07B2 is met. SSDI approved.

Case Three, David, 24, Ohio

David has chronic hydroa vacciniforme confirmed by phototesting, skin biopsy showing intraepidermal vesicles and epidermal necrosis, and EBV testing negative for the lymphoproliferative variant. He has vesicular eruptions with residual scarring across cheeks, forehead, dorsal hands, and forearms. Skin biopsy over three years shows persistent involvement. Multiple treatment attempts with hydroxychloroquine, azathioprine, and thalidomide have not controlled the disease. Extensive lesions have persisted more than 12 months across critical body areas. 8.07B1 is met. SSDI approved.

Case Four, Sofia, 45, California

Sofia has XPV (variant XP) diagnosed at age 42 after her fourth basal cell carcinoma and second squamous cell carcinoma of the face and dorsal hands. Gene panel identified biallelic pathogenic variants in POLH. Clinical features are milder than classic XP with fewer freckles in childhood. She spent her 20s and 30s working outdoors as a garden designer before diagnosis. 8.07A applies. Onset defaults to birth. She may claim retroactive benefits back to the earliest allowable filing date. SSDI approved with claim reviewed for possible earlier onset for back pay purposes.

Denial Counters

Denial reason: no genetic testing on file

Genetic testing is preferred but not always required. Section 8.00E allows diagnosis by clinical findings plus family history plus laboratory findings including UV-induced chromosomal studies. Response is to submit any DNA repair testing performed, sibling genetic testing showing the same variant, or photographic evidence with dermatology clinical notes.

Denial reason: lesions not extensive enough

Extensive under 8.00B2 includes involvement of critical body areas even when the total surface area is small. Response is to point to critical body area involvement (face, hands, ears, lips) and to lay out the 12-month duration in the medical record.

Denial reason: patient can go outside sometimes

For 8.07B2, the analyst may argue that if the patient goes outside at night or in shaded conditions, they can function outside a protective environment. Response is to emphasize the definitional language in 8.00E4. Nighttime, fully shaded, or fully clothed outdoor exposure is still functioning within a highly protective environment because the environment blocks the source of UV radiation. The rule is met when the patient cannot function outside such an environment for 12 continuous months.

Denial reason: XP diagnosis not confirmed

Classic XP clinical features with a compatible family history can support diagnosis when genetic testing has not been done. Response is to arrange genetic testing through the treating dermatologist or a specialty genetics clinic. XPeriment, the Xeroderma Pigmentosum Society, maintains referral resources. Once genetic testing is added, 8.07A is met without any further functional testing.

Cross Reference to Other Body Systems

Neurological XP forms and Cockayne syndrome

XPA and Cockayne syndrome often have neurological involvement that meets Listing 11.17 for degenerative neurological disorders or Listing 12.02 for neurocognitive disorders. Combined 8.07A plus 11.17 claims are strong for XPA patients with progressive neurological decline.

Ocular involvement

XP patients frequently develop photokeratitis, keratitis, corneal opacities, and secondary blindness from cumulative UV damage to the eye. Once vision loss becomes severe, Listing 2.02 for loss of central visual acuity or 2.04 for loss of visual efficiency may apply as a parallel path.

Skin cancer

Melanoma and non-melanoma skin cancers meeting Listing 13.29 for malignant neoplastic diseases of the skin can add a parallel Section 13 claim for XP patients with metastatic disease.

Growth and endocrine involvement

Cockayne syndrome and Bloom syndrome patients often have growth failure and endocrine involvement that gets evaluated through the framework in Section 9.00 which applies across other body systems.

Compassionate Allowance Considerations

Xeroderma pigmentosum is on the SSA Compassionate Allowances list. This means claims are flagged for expedited processing. POMS DI 23022.920 sets out the CAL processing framework for XP. The Compassionate Allowance program moves qualifying claims from the standard 3 to 6 month determination timeline to a target under 30 days when the flagging works correctly. Filing tip: mention CAL on the disability report and reference DI 23022.920 in any cover letter.

Cockayne syndrome is also on the Compassionate Allowances list under a separate entry. Bloom syndrome and other genetic photosensitivity disorders are not currently CAL conditions but may still meet 8.07B on standard processing.

SSDI Versus SSI for Photosensitivity Claimants

XP and similar disorders often disable people from childhood. Congenital disability under 8.07A means many claimants never had a work history and depend on SSI rather than SSDI. Adult XP claimants who worked for many years before diagnosis and who accumulated work quarters may qualify for SSDI or concurrent SSDI plus SSI. The 2026 Federal Benefit Rate for SSI is 967 dollars per month for an eligible individual and 1,450 for an eligible couple.

State Considerations

Rare-disease diagnoses often benefit from filing near major academic centers. See our state pages for large photodermatology programs including California, Texas, New York, Massachusetts, and Pennsylvania. Ohio, Michigan, and Illinois also host active genodermatology clinics.

Related Blog Articles

• Listing 8.08 Burns in 2026 for the sister rule that shares Section 8 but requires functional testing under the four paragraphs.
• Listing 14.07 Immune Deficiency Disorders for XP-related immune complications when they occur.
• Listing 7.18 Repeated Complications of Hematological Disorders for Bloom syndrome cases with hematologic features.

Frequently Asked Questions